required more than 20 days' treatment) . This difference between the two groups was significant. One patient in each group did not respond to sodium stibogluconate, but both were cured with pentamidine. Altogether 104 patients were cured after 20 days' treatment; 20, including the eight who relapsed, were cured after more than 20 days' treatment. There was no significant difference between the two groups in the side effects of the drug, which were minor. The longer courses of treatment (50 days in one patient) were well tolerated.
It is suggested that the traditional six day course of treatment with sodium stibogluconate for kala-azar is grossly inadequate and that a longer course is required to prevent relapse.
Introduction
In the 1970s Bihar province in India experienced a massive epidemic of kala-azar (visceral leishmaniasis), and the disease is still endeniic in some areas. Out of the 400 000 new cases of leishmaniasis in the world in 1977,1 a quarter occurred in Bihar.2 3 Sodium stibogluconate was used as a first line drug during this epidemic. Manson-Bahr's regimen of six days' treatment with sodium stibogluconate,4 still advocated in current editions of most textbooks, '-8 was the standard treatment in India.
A committee of Indian experts suggested that two courses of sodium stibogluconate lasting for 10 days each and interrupted by a break of 10 days should be adequate to treat Indian kala-azar.' This was a modified version of Manson-Bahr's regimen of treatment for Kenyan kala-azar. 9 We had found Manson-Bahr's regimen for Indian kala-azar grossly inadequate, and even with the regimen suggested by the committee of Indian experts the incidence of relapse was high.'0 11 We started to give the drug continuously for 20 days, or even longer in some cases, and the incidence of relapse (0-5%) was almost negligible. '2 This encouraged us to compare in a randomised trial the efficacy, safety, and desirability of giving the drug for 20 days, or longer if necessary. We report the outcome of that trial.
Patients and methods
We undertook this trial to see whether treatment with antimony for 20 days, or longer if necessary, was effective and could be tolerated by Indian patients with kala-azar. A subsidiary aim was to confirm that it is not necessary to give an initial dose of 1 or 2 ml to test for hypersensitivity. On the basis of previous experience, assuming the incidences of drop out and of spontaneous cure to be 0% and the incidence of cure with the standard treatment to be 70%, and with the difference in the incidence of cure between the standard treatment and the new treatment expected to be 20%, we used a sample size of at least 60.13 The study was conducted from January 1981 to November 1982. All patients at this hospital with kala-azar, confirmed by the finding of amastigotes of leishmania (figure) in smears of bone marrow or spleen stained with Giemsa, were included in the study. Patients were excluded if they had haemoglobin concentrations below 3 g/dl; had complications such as pneumonia, jaundice, tuberculosis, or renal disease; or had received treatment with antimony or pentamidine for kala-azar before coming to this hospital. A total of 126 patients (104 men and 22 women (ratio 4-4:1)) were entered into the trial. Equal numbers of men and women were randomly allocated to two treatment groups (see below). Only eight patients in the first group and six in the second were aged under 18.
The clinical state of each patient was thoroughly assessed before the start of treatment. The duration of illness was noted. The spleen was measured in the anterior axillary line from the costal margin to its tip and the liver in the midclavicular line from the costal margin to its margin. Patients' weights were noted. Total and differential counts of white cells, haemoglobin and serum protein concentrations, and serum alanine transaminase and aspartate transaminase activities were measured. A urine examination, chest x ray examination, and electrocardiography were also done in each patient.
REGIMENS OF TREATMENT
Patients aged 12 or more in both groups were given sodium stibogluconate (100 mg antimony/ml) 6 ml daily intramuscularly in the buttocks. Patients aged below 12 received 20 mg antimony/kg body weight/day intramuscularly.
In 63 patients (group 1) the drug was stopped after 20 days. Patients were then assessed clinically: bone marrow or splenic aspiration was repeated and total and differential white cell counts, Leishman-Donovan bodies inside and outside macrophages in smear of aspirate of bone marrow (Giemsa stain) X 1000.
haemoglobin concentration, and serum alanine transaminase and aspartate transaminase activities were measured. Electrocardiography and urine examination were done, and patients were asked to attend for follow up 
Results
Initial clinicalfindinigs-The two groups were comparable (table I) . The main clinical features were intermittent fever, loss of appetite, shivering or rigor, splenohepatomegaly, no lymphadenopathy, leucopenia with monocytosis, and anaemia.
After 20 days of treatment there was no difference in the incidence of initial cure, parasitological cure, or apparent cure between the two groups (table II) . One patient from each group did not respond to antimony but improved with pentamidine.
At six months' follow up 62 patients in group 2 and 54 in group 1 were cured. One patient in each group had not responded to treatment. None of the patients in group 2 but eight of those in group 1 had relapsed: two within 15 days, four within two months, and two within three months. They were all subsequently cured with treatment lasting for more than 20 days (given for 40 days after relapse in five cases and for 30 days in three). Twelve of the patients in group 2 had needed more than 20 days' treatment: eight had been treated for 30 days, three for 40, and one for 50. All 12 patients were slow responders (table III) . Altogether, 54 patients in group 1 and 50 in group 2 (830,, of the total) were cured after 20 days' treatment; and 20 patients (16",,) (12 in group 2 and the eight in group 1 who relapsed) were cured after treatment lasting for more than 20 days. Two patients were cured with pentamidine.
Side effects and tolerance-No side effects developed that were severe enough to necessitate withdrawal of treatment (table IV) . No patients developed a hypersensitivity reaction. All the patients who were given antimony for more than 20 days, including a boy who was given it for 50 days, tolerated it well. 
Discussion
This study shows that 20 days of treatment with sodium stibogluconate is well tolerated and effective in many patients with kala-azar; continuing the drug for longer results in cure in most of the remaining patients. We made several changes in the recommended regimen of treatment for Indian kala-azar: the rest period between the two courses was abolished; the drug was used for longer than ever before in India; and the initial test for hypersensitivity was not done. None of the patients in the group given more than 20 days' treatment if necessary (group 2) relapsed, and the incidence of cure in this group was 98". Of the patients in the group initially given only 20 days' treatment (group 1), eight (13%1) relapsed and 54 (86>)) were cured. This difference in the incidence of cure between the two groups was significant (p=0 02).
Sen Gupta thought that sodium stibogluconate was a much weaker drug than urea stibamine or methylglucamine antimoniates,"5 and the incidence of relapse in his series of patients varied from 10 to 15 ''0 20 days, but by then their conditions had started to deteriorate; in such cases pentamidine was started, to which both patients responded. Unresponsiveness to antimony may arise during the course of treatment and is then called secondary unresponsiveness. A third type of unresponsiveness, relative unresponsiveness, occurs when patients respond only to higher dosages of the drug given for longer periods. In our experience, and in that of other workers,'6 patients labelled as unresponsive improve when the dose of sodium stibogluconate is increased and the duration of treatment prolonged. We have found that a rest period between two courses of treatment encourages unresponsiveness. Fortunately in this series there were only two cases of primary unresponsiveness and none of secondary or relative unresponsiveness. Administration of the drug for longer periods to slow responders might be the reason for this. The drug did not produce any major side effects, but patients complained of pain at the site of injection due to the large doses given. There was no difference in side effects between the two groups. We had feared when the trial was started that the drug might produce serious side effects in patients receiving it for more than 20 days, but they tolerated it well. Neither in this series nor in our previous series of 750 patients" did we come across any case of hypersensitivity to antimony.
We suggest that sodium stibogluconate should be given to Indian patients with kala-azar for more than 20 days if this is indicated without any rest period between courses. A trial is needed to assess the efficacy of higher dosages given for shorter periods.
